Trial Profile
A phase III study of CSP-1103 for the treatment of mild cognitive impairment
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2015
Price :
$35
*
At a glance
- Drugs Itanapraced (Primary)
- Indications Mild cognitive impairment
- Focus Therapeutic Use
- 01 Jul 2015 According to CereSpir media release, company has submitted Special Protocol Assessment (SPA) request to the US FDA to initiate design discussion.
- 20 Jun 2015 New trial record